MP62-19 AKR1C3 OVEREXPRESSION IN PROSTATE CANCER PROMOTES EPITHELIAL-MESENCHYMAL TRANSITION AND METASTASIS VIA ACTIVATION OF MAPK/ERK SIGNALING AND UPREGULATION OF ZEB1
Bin Wang,Kaijie Wu,Jun Huang,Jer Tsong Hsieh,Dalin He
DOI: https://doi.org/10.1016/j.juro.2016.02.927
2016-01-01
Abstract:INTRODUCTION AND OBJECTIVES: AKR1C3, as a crucial steroidogenic enzyme, facilitated intratumoral androgen biosynthesis and androgen receptor (AR) reactivation in the development of castration-resistant prostate cancer. Also, amount of data have shown that AKR1C3 expression was significantly elevated in clinical metastatic prostate cancer (PCa) specimens, indicating an alternative role of AKR1C3 in PCa metastasis. Epithelial-mesenchymal transition (EMT) has been recognized to play pivotal roles in promoting carcinoma invasion and metastasis; however, the roles of AKR1C3 in EMT and PCa metastasis have not been fully elucidated. METHODS: C4-2, 22RV1-T and PC-3 cells with higher AKR1C3 expression were selected and treated with several specific AKR1C3 shRNAs or small molecule inhibitor, and the cell migration and invasion abilities were detected by wound healing assay and Transwell assay. The expression of EMT markers (i.e., E-cadherin and vimentin) and the related transcription factors (i.e., Snail, Slug, ZEB1 and Twist1) was examined by Western blot or quantitative PCR assays, and the phosphorylation of AKT or ERK was detected by Western blot. Also, the expression of vimentin, ZEB1 and p-ERK (T202/Y204) was detected by immunohistochemical staining in PC-3 xenograft tissues after AKR1C3 inhibitor treatment. The correlation between AKR1C3 and EMT markers (including EMT-related transcription factors) expression in clinical specimens from tissue microarray or TCGA database was analyzed. RESULTS: AKR1C3 was overexpressed in more aggressive PCa cell lines regardless of the AR status. Knock-down of AKR1C3 expression or inhibition of AKR1C3 activity could significantly suppressed cell migration and invasion abilities in vitro. Also, knock-down of AKR1C3 expression or inhibition of AKR1C3 activity could increase E-cadherin expression but decrease vimentin expression, in which the phosphorylation of ERK and the transcription factor ZEB1 expression were specifically downregulated. In consistency, inhibition of AKR1C3 activity by inhibitor treatment could decrease the expression of vimentin, ZEB1 and p-ERK (T202/Y204) in xenograft tissues in vivo. Moreover, there was a significant correlation between AKR1C3 and EMT markers (i.e., E-cadherin, vimentin and ZEB1) in human PCa specimens. CONCLUSIONS: AKR1C3 is a novel EMT regulator in PCa metastasis through activation of MAPK/ERK signaling and upregulation of ZEB1 expression.